It's hard to predict whether the Medicare drug price negotiation provision in the Inflation Reduction Act (IRA) could lead to higher or lower prices in the commercial market, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
It's hard to predict whether the Medicare drug price negotiation provision in the Inflation Reduction Act (IRA) could lead to higher or lower prices in the commercial market, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
Could the impact of the Medicare price negotiation provision in the IRA ripple out to employers and commercial health plans?
Well, there are many aspects of Medicare policy, including negotiation for prescription drugs, that the commercial market watches closely. There are many instances where the commercial market will follow suit on a Medicare policy, but there are some examples where it's not. So, some worry that they'll kind of march in lockstep. Others worry that there might be some type of cost shift in the fact that lower prices to the Medicare program might lead to higher prices for commercial payers. But as the great Yogi Berra used to say, predictions are dangerous, particularly those about the future. I tend to not be a prognosticator and leave that up to people who spend more time in the prescription drug arena.
Contributor: Breaking the Cycle—RSAT Program Improving Reentry in Arizona
March 15th 2024Arizona is well suited to benefit from its 1115 demonstration waiver requested from CMS because it already has a robust justice-involved reentry initiative called the Residential Substance Abuse Treatment (RSAT) Program, which is emerging as an archetype of successful reentry programs that can serve as a template for other states to emulate.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
An appeals court rules against the Pharmaceutical Research and Manufacturers of America in a 340B contract pharmacy dispute; for-profit investors’ acquisition of nursing homes has raised concerns about the quality of care provided in these facilities; President Joe Biden’s proposed budget for 2025 includes changes that would do away with the current system of biosimilar interchangeability.
Read More